Despite issues, active surveillance has potential, and surgery has evolved from bad reputa ...

FDA has approved a new first‑line treatment using Ziihera plus chemotherapy and Tevimbra for adults with advanced, ...

Lenvima and Keytruda with chemotherapy did not significantly improve OS in metastatic ESCC compared to Keytruda and chemotherapy alone. Median OS was 17.6 months in the Lenvima arm versus 15.5 months ...

Esophageal cancer is relatively rare, making up only 1% of all cancer diagnoses in the US. However, it is also one of the most deadly cancers — with a five-year survival rate of only 20%.

Esophageal and gastric cancers remain among the deadliest malignancies worldwide, with five-year survival rates generally below 30 per cent in most settings. Survival outcomes depend heavily on tumour ...

Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis Overall, 240 patients were randomly ...

This prospective, observational, cohort study was conducted as part of a multicenter collaboration within the African Esophageal Cancer Consortium (ClinicalTrials.gov identifier: NCT05177393).

Spotting esophageal cancer is something you can do by knowing its common symptoms, primarily dysphagia (persistent swallowing difficulty). Just as crucial is to understand that not all people ...